Actinic prurigo cheilitis: clinicopathologic analysis and therapeutic results in 116 cases.
Objective. This study describes the clinicopathologic features and therapeutic results of 116 patients with actinic prurigo cheilitis seen over an 11-year period. Study Design. A retrospective study was carried out with hospital records and a microscopic slide review from a large dermatology department in Mexico City, Mexico. Results. The study consisted of 42 male (36.2%) and 74 female (63.8%) patients, with a male to female ratio of 1:1.7. Age ranged from 9 to 82 years (mean, 27.9 years; standard deviation, 14.2). Thirty-two cases (27.6%) were found in which cheilitis was the only manifestation of this condition. Pruritus, tingling, and pain of the vermilion were recorded in 96 cases (82.7%). Typical histopathologic findings included in most cases the presence of acanthosis, spongiosis, basal cell vacuolation, ulceration with serohematic crust formation, edema of the lamina propria, lymphocytic inflammatory infiltrate with well-defined lymphoid follicles, and variable numbers of eosinophils and melanophages. Improvement of the symptoms was obtained in 112 cases (96.5%) with sun-protective measures and diverse antiinflammatory agents. However, complete resolution of the labial lesions were more frequently achieved with the combination of topical steroids, thalidomide, and sun-protective measures (42.2%) as compared with topical steroid therapy plus sun-protection measures (16.3%; P <.005). Conclusion. Our findings confirm that lip lesions may appear as the only manifestations of this photodermatosis and that it has typical clinical and microscopic features and should therefore be considered a specific form of cheilitis.
Department of Dermatology, Dr Manuel Gea Gonzalez General Hospital, Mexico City, Mexico.
María Elisa
ME
Vega-Memije
Adalberto
A
Mosqueda-Taylor
María Esther
ME
Irigoyen-Camacho
María Teresa
MT
Hojyo-Tomoka
Luciano
L
Domínguez-Soto
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002613:Cheilitis / Q000150:complications / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology*; D016009:Chi-Square Distribution; D002648:Child; D003879:Dermatologic Agents / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D008875:Middle Aged; D010787:Photosensitivity Disorders / Q000188:drug therapy / Q000473:pathology*; D011536:Prurigo / Q000150:complications / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D012044:Regression Analysis; D012189:Retrospective Studies; D013472:Sunlight / Q000009:adverse effects; D013473:Sunscreening Agents / Q000627:therapeutic use; D013792:Thalidomide / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D004338:Drug Combinations; D005938:Glucocorticoids; D013473:Sunscreening Agents; D013792:Thalidomide